A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

Sponsor: Hoffmann-La Roche

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT06267001

Patient View

This study assesses the efficacy and safety of tiragolumab plus atezolizumab versus placebo plus atezolizumab in NSCLC patients post-resection and chemotherapy. Eligible participants have Stage IIB-IIIB NSCLC, ECOG status 0-1, PD-L1 expression ≥1%, and adequate recovery from surgery and chemotherapy. Interventions include IV administration of atezolizumab, tiragolumab, or placebo.

Patient Parameters

Program Overview

The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered to participants with non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy.

Eligibility Criteria

Inclusion Criteria

  • Eastern Cooperative Oncology Group performance status of 0 or 1
  • Histological or cytological diagnosis of Stage IIB, IIIA, and select IIIB NSCLC of either non-squamous or squamous histology
  • Participants must have had complete resection of NSCLC
  • Participants must have received between one to four cycles of adjuvant histology-based platinum doublet chemotherapy
  • Participants must have recovered adequately from surgery and from adjuvant chemotherapy
  • Tumor cell PD-L1 expression at >/= 1%
  • Adequate hematologic and end-organ function.

Exclusion Criteria

  • Any history of prior NSCLC within the last 5 years
  • Any evidence of residual disease or disease recurrence following surgical resection of NSCLC, or during or following adjuvant chemotherapy
  • NSCLC known to have mutation in the EGFR gene or an ALK fusion oncogene

Get This Program In Your Inbox

You can sign up and apply your patients for this program.